News Release Details
News Release Details
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern
“This ongoing social media initiative has been implemented as part of Napo’s efforts to encourage mobilization of patients. We believe that when patients feel empowered, they are more likely to engage in discussions with their health care providers about supportive care options for often-neglected conditions such as HIV-related diarrhea,”
The upcoming Facebook Live discussion, titled Balancing Advocacy with Life, is the third event in the monthly “HIV Community Conversations” series, which brings key advocates and activists in the HIV community together to talk about the issues that matter most to people living with and affected by HIV/AIDS. Laffrey and Robbins will discuss overcoming advocacy burnout and how to maintain balance when there is so much important advocacy work to be done.
Laffrey is an international HIV advocate, speaker and consultant. Since her diagnosis in 2003, she has worked to empower others living with the virus and at risk to look beyond the stigma of HIV by challenging self-esteem, abandonment, distrust and other barriers towards healing, inspiration and victorious living. In sharing her personal expertise, Laffrey provides individuals and groups the platforms needed to have conversations that will change how stigma is addressed. Through her public health bistro campaigns: speaking, one-on-one peer counseling, workshop development, social media outreach, and program consulting, she emphasizes empowerment, sexual responsibility, and development of spiritual principles for individuals all over the world.
Robbins is an HIV activist, blogger, writer, social media marketer, and a consultant to Napo. He was recently honored with the
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s belief that when patients feel empowered, they are more likely to engage in discussions with their health care providers about supportive care options for often-neglected conditions such as HIV-related diarrhea, and the belief that efforts which may help drive conversations about HIV-related diarrhea between patients and their caregivers will support the Company’s goal of expanding the number of primary care providers who are aware of Mytesi’s benefits and prescribe the drug. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.